Displaying drugs 14951 - 14975 of 15155 in total
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.
Experimental
Matched Description: … (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and …
Elinzanetant
Elinzanetant is under investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and How Safe It Is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)).
Investigational
Matched Description: … investigation in clinical trial NCT05099159 (A Study to Learn More About How Well Elinzanetant Works and …
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … orally administered drug candidate under development by Merck for the treatment of atherosclerosis and …
Avasopasem manganese
Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19.
Investigational
Matched Description: … [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis …
VSF-173
VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive...
Investigational
Matched Description: … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression …
CHF 4227
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
Matched Description: … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone …
8-chlorotheophylline
8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with Diphenhydramine as the antiemetic drug Dimenhydrinate. The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous...
Experimental
Matched Description: … chlorotheophylline produces a number of effects including nervousness, restlessness, insomnia, headache, and …
R411
R411 is a non-steroid oral medicine for the treatment of asthma. It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to...
Investigational
Matched Description: … It is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory …
ND1251
ND1251 is an orally active phosphodiesterase-4 (PDE4) inhibitor, a mechanism clinically proven to play a role in alleviating symptoms of depression. ND1251 is a very potent compound with a large safety margin. ND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and...
Investigational
Matched Description: … applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and …
6-Methylamino-5-Nitroisocytosine
Experimental
WT-1 A1
Investigational
Matched Iupac: … carbamoylpropanamido]propanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-4-methylpentanoic acid …
Displaying drugs 14951 - 14975 of 15155 in total